Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Neonatal Perinatal Med ; 10(1): 1-7, 2017.
Article in English | MEDLINE | ID: mdl-28304315

ABSTRACT

INTRODUCTION: Although antifibrinolytic agents are used to prevent and treat hemorrhage, there are concerns about a potential increased risk for peripartum venous thromboembolism. We sought to determine the impact of tranexamic acid and ɛ-aminocaproic acid on in vitro clotting properties in pregnancy. METHODS: Blood samples were obtained from healthy pregnant, obese, and preeclamptic pregnant women (n = 10 in each group) prior to delivery as well as from healthy non-pregnant controls (n = 10). Maximum clot firmness (MCF) and clotting time (CT) were measured using rotation thromboelastometry in the presence of tranexamic acid (3, 30, or 300 µg/mL) or ɛ-aminocaproic acid (30, 300, or 3000 µg/mL). ANOVA and regression analyses were performed. RESULTS: Mean whole blood MCF was significantly higher in healthy pregnant vs. non-pregnant women (66.5 vs. 57.5 mm, p < 0.001). Among healthy pregnant women, there was no significant difference between mean MCF (whole blood alone, and with increasing tranexamic acid doses = 66.5, 66.1, 66.4, 66.3 mm, respectively; p = 0.25) or mean CT (409, 412, 420, 424 sec; p = 0.30) after addition of tranexamic acid. Similar results were found using ɛ-aminocaproic acid. Preeclamptic women had a higher mean MCF after the addition of ɛ-aminocaproic acid and tranexamic acid (p = 0.05 and p = 0.04, respectively) compared to whole blood alone. CONCLUSIONS: Pregnancy is a hypercoagulable state, as reflected by an increased MCF compared to non-pregnant women. Addition of antifibrinolytic therapy in vitro does not appear to increase MCF or CT for non-pregnant, pregnant, and obese women. Whether antifibrinolytics are safe in preeclampsia may require further study.


Subject(s)
Aminocaproic Acid/pharmacology , Antifibrinolytic Agents/pharmacology , Blood Coagulation/drug effects , Fibrinolytic Agents/pharmacology , Tissue Plasminogen Activator/pharmacology , Tranexamic Acid/pharmacology , Adult , Aminocaproic Acid/therapeutic use , Antifibrinolytic Agents/therapeutic use , Case-Control Studies , Female , Humans , In Vitro Techniques , Obesity/blood , Peripartum Period , Postpartum Hemorrhage/drug therapy , Postpartum Hemorrhage/prevention & control , Pre-Eclampsia/blood , Pregnancy , Pregnancy Complications/blood , Pregnancy Trimester, Third , Thrombelastography , Tranexamic Acid/therapeutic use , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...